News

Press Releases

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases • The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases Munich, Germany, April 26, 2022 –– ViGeneron GmbH, a next-generation gene therapy […]

ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

• Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product • ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, development and commercial milestone payments, plus royalties on net sales • The collaboration […]

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

ViGeneron has announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections.

ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership For Next-Generation Ophthalmic Gene Therapy

ViGeneron has announced a strategic partnership with WuXi Advanced Therapies Inc., a leading Contract, Testing, Development and Manufacturing Organization to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program.

ViGeneron Announces Closing of Series A Financing to Drive Development of Next Generation Gene Therapy Pipeline

ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. Funds will advance development of ViGeneron’s […]

Events

There are no events scheduled at the moment

In The Media

Bioworld: Vigeneron carves out space in evolving AAV gene therapy landscape

Although gene therapy is now “a clinical reality,” it still remains an early stage therapeutic modality. That’s the view of Caroline Man Xu, CEO and co-founder of Vigeneron GmbH, a German gene therapy company that has maintained a low profile while steadily staking out a promising position in gene therapies for inherited retinal disease.   […]

PharmaTimes: ViGeneron and Daiichi Sankyo to develop therapy for eye diseases

Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates ViGeneron and Daiichi Sankyo have agreed a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vGAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases. The two companies have been working on a programme together […]

Fierce Biotech: Hunting for next big eye disease drug, Regeneron gets deeper into gene therapies with ViGeneron pact

Regeneron is dipping its toe deeper into the gene therapy waters, teaming up with ViGeneron to work on a retinal disease prospect based on engineered recombinant adeno-associated virus vectors (vgAAVs). While best known for its antibody work, Regeneron has a history of exploring other modalities through dealmaking, inking a $640 million gene therapy pact with Avalanche […]

Endpoints News: Building on its retinal disease expertise, Regeneron signs eye-focused gene therapy pact with German biotech

Regeneron beefed up its gene therapy capabilities Wednesday, signing a new deal with the German biotech ViGeneron. The similarly named — but unrelated — companies announced the collaboration early Wednesday morning, one which would see ViGeneron receive undisclosed upfront and milestone payments in exchange for Regeneron getting access to its suite of recombinant adeno-associated virus […]

Biopharma Dive:Regeneron, in search of an eye gene therapy, turns to a young biotech

Dive Brief: • Through a deal announced Wednesday, a German-based biotechnology company has agreed to help Regeneron develop a gene therapy for an inherited retinal disease. • The company, ViGeneron, claims to have an improved method for engineering the viral vehicles often used to shuttle genetic medicine into the proper cells. So far, ViGeneron’s research […]

Endpoints News: Edging toward a pivotal readout, Biogen picks a new discovery partner for ophthalmic gene therapy

Almost two years after Biogen swooped again into the ophthalmic gene therapy field with an $800 million buyout of eye-focused Nightstar Therapeutics, it’s turning to a young player for a new program. Germany’s ViGeneron will be deploying its next-generation AAV vectors to generate candidates for a target — Biogen isn’t disclosing which exactly — that […]

S&P Global: ViGeneron collaborates with Biogen to develop gene therapies for eye diseases

ViGeneron GmbH is collaborating with Biogen Inc. to develop gene therapies for the treatment of inherited eye diseases. The companies will use Germany-based ViGeneron’s proprietary vgAAV gene therapy vector technology to efficiently transduce retinal cells by injecting medicine into the eye. ViGeneron, a gene therapy developer, will focus on optimizing and validating therapies for an […]

Genengnews: ViGeneron and WuXi Form Strategic Manufacturing Partnership

ViGeneron, a gene therapy company, and WuXi Advanced Therapies, a contract, testing, development, and manufacturing organization (CTDMO), entered into a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program. ViGeneron’s lead product, VG901, targets a disease gene for Retinitis pigmentosa (RP), for which there is currently no […]

Pharmaphorum: ViGeneron to develop next-gen eye gene therapies after funding round

Germany’s ViGeneron is to advance development of its next-generation ophthalmology gene therapy pipeline after a series A financing round. The privately-owned Munich-based biotech did not say how much it had raised from the financing round, which was led by WuXi AppTec and Sequoia Capital China. But ViGeneron said the proceeds will allow it to accelerate […]